# A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

> **NCT04645966** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 326 (actual)

## Conditions studied

- Meningococcal Vaccine

## Interventions

- **BIOLOGICAL:** MenABCWY
- **BIOLOGICAL:** Bivalent rLP2086 (60-µg Dose)
- **BIOLOGICAL:** Bivalent rLP2086 (120-µg Dose)
- **BIOLOGICAL:** Bexsero
- **DRUG:** Prophylactic Liquid Paracetamol (PLP)
- **BIOLOGICAL:** Nimenrix
- **OTHER:** Placebo
- **DRUG:** Scheduled Liquid Paracetamol (SLP)
- **DRUG:** Therapeutic Liquid Paracetamol (TLP)

## Key facts

- **NCT ID:** NCT04645966
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-26
- **Primary completion:** 2022-09-15
- **Final completion:** 2022-09-15
- **Target enrollment:** 326 (ACTUAL)
- **Why stopped:** The Sponsor decided to discontinue the study based on Sponsor's careful review of available safety data in concert with the recommendation of an independent Data Monitoring Committee.
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04645966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04645966, "A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04645966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*